Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
Watch the Most Recent Recordings
Potential Pathways for Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
Explore the different imaging modalities currently being used in AL and ATTR amyloidosis. Identify knowledge gaps impeding their implementation as validated tools that can serve as endpoints adequate for drug approval in interventional clinical trials.